Chrysos Secures $200 Million Debt Facility to Accelerate PhotonAssay Growth
Chrysos Corporation has refinanced its debt with a $200 million syndicated facility, enhancing financial flexibility to accelerate manufacturing and deployment of its PhotonAssay technology worldwide.
- New $200 million three-year corporate debt facility replaces asset-based financing
- Facility improves pricing, covenants, and increases funding headroom by $105 million
- Supports target manufacturing cadence of 18 PhotonAssay units annually
- Forward order book includes 22 units and 27 long-lead components
- Strong commercial momentum with 23 lease agreements signed year-to-date
Major Refinancing Enhances Chrysos’ Growth Capital
Chrysos Corporation Ltd (ASX:C79) has secured a fresh $200 million syndicated debt facility, replacing its previous asset-based financing with a corporate-style facility that offers greater operational flexibility. The three-year loan, provided by ANZ, National Australia Bank, and Export Finance Australia, brings improved debt pricing, reduced commitment fees, and enhanced covenants. Notably, it increases Chrysos’ funding headroom by $105 million, providing a substantial capital boost to support its growth ambitions.
Backing Global Deployment of PhotonAssay
The new facility is explicitly designed to fuel the development, production, and deployment of Chrysos’ flagship PhotonAssay™ units across multiple jurisdictions, including Australia, Canada, New Zealand, the UK, and the US, with scope to add more regions. Chrysos aims to return to its target manufacturing cadence of 18 units per year, underpinned by a forward order book comprising 22 PhotonAssay units and 27 long-lead components. This pipeline positions the company to meet anticipated demand through FY27 and beyond.
Sustained Commercial Momentum in PhotonAssay Adoption
Chrysos continues to build on strong commercial momentum, having signed 23 PhotonAssay lease agreements year-to-date, including four new contracts since its last update. The expanding global footprint features partnerships with major laboratories such as SGS and ALS, with the latter receiving its second unit in Saudi Arabia. The company also marked its third consecutive month processing over one million samples, reflecting high utilisation rates across its PhotonAssay fleet amid a buoyant gold market. Currently, two units are being deployed across two regions, highlighting ongoing expansion efforts.
CEO Highlights Strategic Flexibility and Growth Potential
Chrysos CEO Dirk Treasure emphasised the strategic importance of the new facility, stating it provides the flexibility and capital necessary to scale deployments and expand the company’s global footprint. He pointed to the accelerating deployment cadence and strong demand as drivers of continued growth. The facility’s structure supports Chrysos’ ambition to maintain momentum as customer adoption of PhotonAssay strengthens worldwide.
Bottom Line?
Chrysos’ new debt facility significantly enhances its capacity to scale PhotonAssay deployments, setting the stage for growth; but execution on manufacturing and global expansion will be critical to justify this increased leverage.
Questions in the middle?
- How will Chrysos manage supply chain and manufacturing challenges to meet its 18 units per year target?
- What impact will the increased debt facility have on Chrysos’ future profitability and cash flow?
- Can Chrysos sustain its commercial momentum amid evolving market conditions and competition?
